Dexcom warns of stolen G7 glucose sensors sold by unauthorized dealer

Patients using Dexcom G7 glucose sensors are being told to check their lot numbers immediately after the company said stolen scrapped devices were sold through an unauthorized dealer. Two affected lots, 1725204004 and 1725069002, were marked for destruction but disappeared during the scrap process and later surfaced in third-party sales.

Dexcom said one lot may raise the risk of skin infection, while the other may produce no readings at all. The company said it had not received reports of severe adverse events tied to the stolen sensors, but the safety issue is serious because the G7 is a core diabetes-management device and users rely on it for continuous glucose data.

Anyone who suspects they bought one of the affected sensors should stop using it, check the lot number on the packaging or device materials, and contact Dexcom right away at 1-844-478-1600 for a replacement. Pharmacies and distributors that received product from Pharmsource LLC, the unauthorized seller Dexcom traced the sales to, should review their inventory carefully. Dexcom said customers can also use its theft-check page to verify lot numbers and should follow up with their health-care provider if a sensor is causing skin irritation, infection concerns, or readings that do not match symptoms.

The company said the problem was uncovered through ongoing quality and accounting reviews on May 26, 2026, and that it is working with the U.S. Food and Drug Administration and other authorities. Dexcom said the stolen material had been designated as scrap because it did not meet company standards, and the theft appears to have happened during the handoff to a third-party vendor responsible for destruction and recycling.

Dexcom said Pharmsource LLC is not an authorized distributor, even though it supplies some independent pharmacies and durable medical equipment distributors in the United States. The company said pharmacies and distributors buying through its authorized channels are not affected, and that U.S. customer communications are being prioritized ahead of notices to users outside the United States.

The episode exposes a weak point in medical-device security: products can move from scrap bins back into the market if chain-of-custody controls fail. Dexcom’s G7 received FDA clearance on December 8, 2022 for people ages 2 and older, and the company later won clearance for the G7 15 Day version for U.S. adults 18 and older in April 2025. That makes the theft more than a warehouse crime. It is a warning about how quickly compromised diabetes supplies can reach patients when the supply chain breaks.